Vimarsana
Biggest News Aggregation in the World

Page 20 - Immunic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Today - Breaking & Trending Today

Immunic, Inc. (NASDAQ:IMUX) CFO Buys $10,640.00 in Stock - Vimarsana News

Immunic, Inc. (NASDAQ:IMUX) CFO Buys $10,640.00 in Stock

Immunic, Inc. (NASDAQ:IMUX – Get Rating) CFO Glenn Whaley bought 3,500 shares of the company’s stock in a transaction dated Friday, June 3rd. The stock was acquired at an average price of $3.04 per share, for a total transaction of $10,640.00. Following the acquisition, the chief financial officer now directly owns 12,568 shares in the […]

Immunic, Inc. (NASDAQ:IMUX) CEO Daniel Vitt Acquires 5,000 Shares - Vimarsana News

Immunic, Inc. (NASDAQ:IMUX) CEO Daniel Vitt Acquires 5,000 Shares

Immunic, Inc. (NASDAQ:IMUX – Get Rating) CEO Daniel Vitt purchased 5,000 shares of Immunic stock in a transaction on Friday, June 3rd. The stock was bought at an average price of $3.10 per share, for a total transaction of $15,500.00. Following the completion of the acquisition, the chief executive officer now owns 368,877 shares in […]

Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Hold" by Analysts - Vimarsana News

Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Hold" by Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) have been assigned a consensus rating of “Hold” from the six analysts that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that […]

DGAP-News: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update - Vimarsana News

DGAP-News: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Issuer: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update - Vimarsana News

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and...